focus -WSS

focus

author：comprehensive 2025-08-20 09:42:21 - browse：83885

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Drug repurposing or repositioning? The language matters

hotspot

WSS

STAT Boddities: What happens to the brain when we get scared?

Here’s what’s in the FDA plan to include pregnant women in clinical trials

STAT Boddities: What happens to the brain when we get scared?

Bernie Sanders gets little from pharma CEOs on drug prices

Psychedelics group wrestles with new pharma identity

Cancer drug shortages should be causing more outrage

focus

focus

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

Doctors on social media are being harassed and cyberbullied

BioMarin wins approval for gene therapy to treat hemophilia A

Drug repurposing or repositioning? The language matters

Virginia high school admissions case could be legal follow

Tome Biosciences co

Medicare proposal to cover medical devices draws a mixed reaction

Dobbs anniversary: the lost opportunity of abortion as health care

Novavax promises a turnaround & Lilly roils the obesity market

DIEP, the 'gold standard' of breast reconstruction, is under threat

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

In Memoriam: Notable people who died in 2023

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Peter Hotez and the public health issue of online harassment

Wikipedia

hotspot

Wikipedia

entertainment